apatinib: Clinical Trials

383 trials of apatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

217 unknown, 53 recruiting, 50 completed, 30 not yet recruiting. 383 Phase 2, 32 Phase 1, 19 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2383Unknown 217, Recruiting 53, Completed 50, Not yet recruiting 30, Active not recruiting 14, Terminated 9, Withdrawn 8, Enrolling by invitation 1, Suspended 1
Phase 132Unknown 25, Completed 3, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 319Unknown 8, Recruiting 5, Active not recruiting 2, Completed 2, Not yet recruiting 2

Follow apatinib: new trials by email Literature Review of apatinib trials Research Report on apatinib

Trials (filtered) newest first · largest first

All 383 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Apatinib mesylate, Physician's choice chemotherapy - Breast Neoplasms, Advanced Breast Cancer
Phase 2Not yet recruitingYunnan Cancer Hospital562027-03-012026-10-30
Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis
Retlirafusp alfa + nab-paclitaxel + apatinib, HEPIC - Gastric Cancer (Diagnosis)
Phase 2Not yet recruitingAnhui Provincial Cancer Hospital322026-11-202026-10-29
Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC
Retlirafusp alfa, zeprumetostat, apatinib - Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruitingFudan University552026-10-012026-10-14
A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma
Retlirafusp Alfa Injection - Melanoma, Immune Checkpoint Inhibitor
Phase 2RecruitingSun Yat-sen University272026-09-292026-11-13
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
SHR-1701, Apatinib, gemcitabine - Metastatic Pancreatic Cancer
Phase 1 / Phase 2RecruitingWest China Hospital452026-09-212026-11-09
Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer
Retlirafusp Alfa, Apatinib, Fluoropyrimidine-Based Chemotherapy - Pancreatic Cancer
Phase 2Not yet recruitingTang-Du Hospital372026-08-302026-08-19
A Study of Combination Therapy in Patients With Resectable Liver Cancer
Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib - Liver Cancer (Primary and Metastatic)
Phase 2Not yet recruitingAffiliated Hospital of Guangdong Medical University682026-08-012026-07-06
SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
Retlirafusp alfa Injection, apatinib - Advanced Unresectable Hepatocellular Carcinoma
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences802026-08-012026-08-06
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate Tablets - Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
Phase 2Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.1202026-07-012026-07-02
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma
Phase 2 / Phase 3Not yet recruitingPeking University Cancer Hospital & Institute902026-07-012026-06-17
Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation
Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib - Rectal Cancer Patients
Phase 2Active not recruitingHarbin Medical University432026-05-292026-07-07
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care - HCC
Phase 2 / Phase 3RecruitingGuangzhou Virotech Pharmaceutical Co., Ltd.662026-05-132026-10-30
Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
Retlirafusp alfa + Apatinib + Nab-paclitaxel - Gastric Adenocarcinoma
Phase 2Not yet recruitingHenan Cancer Hospital502026-05-052026-05-28
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
SHR-1701, apatinib, S-1 & Oxaliplatin - Gastric Adenocarcinoma
Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University802026-04-032026-07-16
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Liposomal Irinotecan, Apatinib in arm1 - Osteosarcoma, Osteosarcoma Metastatic
Phase 1 / Phase 2RecruitingPeking University People's Hospital562026-03-052026-03-18
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib - Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
Phase 2Not yet recruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School862026-02-012026-01-20
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Adebrelimab Injection, Apatinib Mesylate Tablets - Small Cell Lung Carcinoma
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute442026-01-312026-01-22
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
The triple-therapy strategy of Ivarmacitinib, Apatinib, and Camrelizumab - Hepatocellular Carcinomas, Resistance to Immunotherapy
Phase 2Not yet recruitingFirst Affiliated Hospital of Chongqing Medical University652026-01-012026-01-07
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
SHR-1701+Rivoceranib + SHR-2554, SHR-1701 + Rivoceranib - Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
Phase 2RecruitingJingdong Zhang402026-01-012025-12-31
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma
Phase 2 / Phase 3Not yet recruitingShanghai Zhongshan Hospital2222025-12-222025-12-30

Showing 20 of 383. Sign in to see all of them.

Conditions studied

Stomach Neoplasms (40)  ·  Carcinoma, Hepatocellular (33)  ·  Carcinoma, Non-Small-Cell Lung (18)  ·  Breast Neoplasms (16)  ·  Small Cell Lung Carcinoma (16)  ·  Colorectal Neoplasms (15)  ·  Sarcoma (13)  ·  Ovarian Neoplasms (12)  ·  Esophageal Squamous Cell Carcinoma (10)  ·  Triple Negative Breast Neoplasms (10)  ·  Cholangiocarcinoma (9)  ·  Nasopharyngeal Carcinoma (9)  ·  Biliary Tract Neoplasms (8)  ·  Lung Neoplasms (8)  ·  Osteosarcoma (8)

Sponsors

Sun Yat-sen University (24)  ·  Fudan University (18)  ·  Henan Cancer Hospital (14)  ·  Tianjin Medical University Cancer Institute and Hospital (14)  ·  Fujian Cancer Hospital (12)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (12)  ·  Jiangsu HengRui Medicine Co., Ltd. (11)  ·  Peking Union Medical College Hospital (10)  ·  Peking University Cancer Hospital & Institute (10)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8)  ·  Chinese Academy of Medical Sciences (8)  ·  Shanghai Zhongshan Hospital (8)  ·  West China Hospital (7)  ·  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (6)  ·  Sichuan Cancer Hospital and Research Institute (6)

Countries

China (316)  ·  South Korea (5)  ·  United States (2)

Top investigators

Wei Deng, M.D. (3)  ·  Binghe Xu (2)  ·  Chenping Zhang, M.D. (2)  ·  Jun Zhou (2)  ·  Li Xiao, Doctor (2)  ·  Wei Guo, M.D. (2)  ·  Wei Jiang, Ph.D. (2)  ·  Xiaohui He, B.D. (2)  ·  Xin Huang, MD (2)  ·  YunPeng Liu, PhD (2)  ·  Zhenggang Zhu (2)  ·  Aiping Zhou (1)  ·  Bang-De Xiang, Ph.D (1)

Results publications

PMID 26884585, PMID 23918952, PMID 18172173, PMID 18971936, PMID 21183517, PMID 21296855, PMID 21742485, PMID 24292957, PMID 32376724, PMID 32448804, PMID 37580352, PMID 12826431, PMID 15864277, PMID 17018256, PMID 17105988, PMID 17949799, PMID 19331206, PMID 20375404, PMID 20923544, PMID 23464465, PMID 23510598, PMID 24024839, PMID 24140268, PMID 24307987, PMID 24472472, PMID 24484722, PMID 24500024, PMID 24511038, PMID 24581682, PMID 24607285, PMID 24637997, PMID 24950987, PMID 25299232, PMID 25366685, PMID 25376790, PMID 25862517, PMID 26341920, PMID 26755520, PMID 28027849, PMID 28352185, PMID 28444622, PMID 28596446, PMID 28935273, PMID 29245310, PMID 29663291, PMID 30026059, PMID 30053006, PMID 30082170, PMID 30348638, PMID 31109809